Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Allarity Therapeutics initiates phase II trial of Ixempra in Europe for the treatment of metastatic breast cancer

Written by | 21 Mar 2021 | Oncology

Allarity Therapeutics A/S announced that it has enrolled the first patient in its European Phase II clinical trial of Ixempra (ixabepilone) for the treatment of metastatic breast cancer.

The FDA approved Ixempra, a microtubulin inhibitor, in 2007 for the treatment of metastatic breast cancer. Allarity holds exclusive European option rights to Ixempra from the pharmaceutical company R-Pharm U.S., LLC, which previously acquired global rights to the drug from Bristol-Myers Squibb (BMS). Allarity has previously developed and validated a Drug Response Predictor (DRP) companion diagnostic specific for the drug.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.